Pediatric FH


4th EAS Pediatric Familial Hypercholesterolemia symposium

Saturday 03 October, Geneva Switzerland

This event will take place in the Royal Manotel Hotel (Address: Rue de Lausanne 41, 1201 Genève)


Register for FREE here

Registration will close on September 25, 2020

Organized by: Dr Nathalie Brun and Dr Diana Ballhausen



10.00-10.05 Welcome and dedication to Gaby Hanauer-Mader

Steve Humphries

10.05 – 11.30 Topic 1 – Safety and efficacy of lipid lowering treatments

Chair: Nathalie Brun and Albert Wiegman

  • How big is the risk of fetal anomalies due to statin use in pregnancy? – Meeike Kusters (Holland)
  • FH and Pregnancy – results of a survey – Kirsten Holven (Norway)
  • Safety and efficacy of use of evolocumab in children – Albert Wiegman (Holland)
  • Liver transplantation in HOZ FH – Is this only a last resort treatment? –  Jeanine Roeters van Lennep (Holland)
  • Pediatric HoFH trial with lomitapide and recent data – Luis Masana (Spain)
  • Mutation spectrum and genotype-phenotype analysis in children with FH in the IAS FH Pediatric Register – Marta Futema (UK)
11.30 – 12.00 Coffee Break
12.00 – 13.00 Topic 2 – Update on FH Genetics

Chair: Michal Vrablik and Andre Miserez

  • Genetics of FH in Switzerland – Andre Miserez (Switzerland)
  • New genes causing FH – update from the UK 100,000 genome project – Antoine Rimbert (France)
  • How to handle the findings of a VUS in an index case – In silico predictions, AMCG criteria and in vitro Assays – Mafalda Bourbon (Portugal) and Tomas Freiberger (Czech Republic)
  • High triglycerides in children – how high before we get worried? – Michal Vrablik (Czech Republic)
13.00-14.00 Lunch 
14.00-16.00 Topic 3 – Universal Screening for FH in childhood

Chair: Steve Humphries and Sam Gidding

  • What do Patients value most about a diagnosis of FH and how this can be used as part of evidence of clinical utility – Jules Payne (UK)
  • The Russian Experience – Marat Ezhov (Russia)
  • The Bavaria Project – Wolfgang Koenig (Germany)
  • The Berlin and Mecklenburg experience – Elizabeth Steinhagen-Thiessen (Germany)
  • Early Exposure to high LDL-C and future CHD risk – trajectory analysis – Andrew Moran (USA)
  • The Australian experience – Gerald Watts (Australia)
  • Are statin treated FH children at higher risk of T2D? – Justin Zachariah (USA)
  • How concerned should we be about high Lp(a) in children as a future CHD risk factor? – Martin Bogsrud (Norway)
16.00 – 18.00 Discussion


*The symposium is free of charge for all delegates. Please note that a no-show fee of €100 will be charged if you cancel your participation later than Friday 25 Sep or do not show up at the symposium.